Cisplatin-based chemoradiotherapy vs. cetuximab-based bioradiotherapy for p16-positive oropharyngeal cancer: an updated meta-analysis including trials RTOG 1016 and De-ESCALaTE

Znanstveni rad - Pregledni rad

• Autor: Petar Suton
• Autor: Marko Skelin
• Autor: Zoran Rakušić
• Autor: Stjepan Dokuzović
• Autor: Ivica Lukšić
• Autorova ustanova: Sveučilište u Zagrebu; Medicinski fakultet; (KATEDRA ZA MAKSILOFACIJALNU KIRURGIJU SA STOMATOLOGIJOM)
• Znanstveno / umjetničko područje, polje i grana: BIOMEDICINA I ZDRAVSTVO; Kliničke medicinske znanosti; Kirurgija

Sažetak (engleski)

Purpose: Human papilloma virus (HPV)-associated oropharyngeal cancer (OPC) is a special entity among head and neck squamous cell carcinomas (HNSCCs). Given its favorable prognosis, one of the de-escalating strategies in the treatment of OPC includes the introduction of cetuximab (C225) instead of cisplatin (CDDP) in conjunction with radiotherapy. An updated meta-analysis of published studies has been performed, which directly compared the efficacy of CDDP vs. C225 given concurrently with radiotherapy as definitive treatment of p16-positive OPC.
-----
Methods: A systematic literature search was performed for studies published between 2006 and 2018. A total of 1490 citations were obtained and 8 studies met inclusion criteria, with a total of 1665 patients.
-----
Results: The data from seven studies were available for the analysis of 2-year overall survival (OS). Calculated pooled OR for CDDP-based chemoradiotherapy vs. C225-based bioradiotherapy, was 0.45 (P < 0.0001). The data from eight studies were available for the analysis of 2-year locoregional recurrence (LRR). Calculated pooled OR for CDDP-based chemoradiotherapy vs. C225-based bioradiotherapy was 0.35 (P < 0.0001). Patients receiving CDDP with irradiation had 2.2- and 2.9-fold decreased risk for death from any cause and LRR, respectively.
-----
Conclusions: For patients with HPV-positive OPC, radiotherapy plus C225 showed inferior OS and higher LRR rates compared with radiotherapy plus CDDP. CDDP-based chemoradiotherapy should remain standard of definitive treatment of p16-positive OPC.

• Ključne riječi (engleski): Adult; Aged; Antineoplastic Agents / administration & dosage; Cetuximab / administration & dosage; Chemoradiotherapy; Cisplatin / administration & dosage; Female; Humans; Male; Middle Aged; Neoplasm Recurrence, Local / epidemiology; Odds Ratio; Oropharyngeal Neoplasms / mortality; Oropharyngeal Neoplasms / therapy; Oropharyngeal Neoplasms / virology; Papillomaviridae; Squamous Cell Carcinoma of Head and Neck / mortality; Squamous Cell Carcinoma of Head and Neck / therapy; Squamous Cell Carcinoma of Head and Neck / virology; Survival Analysis
• Jezik: engleski
• Vrsta publikacije: Znanstveni rad - Pregledni rad
• Status objave: Objavljen
• Vrsta recenzije: Recenziran
• Verzija publikacije: Završna verzija rukopisa prihvaćena za objavljivanje (postprint)
• Naslov časopisa: European Archives of Oto-Rhino-Laryngology
• Brojčani podaci: vol. 276, br. 5, str. 1275-1281
• p-ISSN: 0937-4477
• e-ISSN: 1434-4726
• DOI: https://doi.org/10.1007/s00405-019-05387-8
• URN:NBN: urn:nbn:hr:105:503286
• Datum objave publikacije: 2019-05
• URL dokumenta: http://link.springer.com/10.1007/s00405-019-05387-8
• Vrsta resursa: Tekst
• Prava pristupa: Otvoreni pristup
• Datum i vrijeme pohrane: 2021-03-17 11:20:20